GM-CSF Promotes Superior In Vitro Differentiation of MHC II+ CD11c+ APCs Compared to L-929 Supernatant in Mouse Bone Marrow Cultures

Antigen-presenting cells (APCs) play a critical role in modulating immune responses, making the optimization of their differentiation protocols essential for advancing cell-based immunotherapies. This study evaluated eight protocols to differentiate APCs from bone marrow precursors of C57BL/6J mice, comparing the effects of GM-CSF and L-929 conditioned supernatants at various concentrations. Four groups treated with GM-CSF and four with L-929 supernatant, alongside a control group, were assessed. Flow cytometry analysis revealed that GM-CSF significantly increased the yield of CD11c+ MHC II+ cells by up to 6-fold compared to the L-929 supernatant. Furthermore, GM-CSF-treated groups showed higher mean fluorescence intensities (MFI) for critical markers such as MHC II and CD11c, with MFI levels surpassing those of SL-929-treated groups by approximately 3- to 5-fold. In contrast, the L-929 supernatant demonstrated limited efficacy in promoting both cell differentiation and surface marker expression, resulting in minimal phenotypic and quantitative gains compared to controls. These findings highlight the superior efficiency of GM-CSF in driving APC differentiation and underscore the importance of balancing cell yield and phenotypic fidelity when selecting differentiation protocols. This study provides valuable insights for researchers developing targeted immunotherapies and offers a solid foundation for optimizing APC-dependent therapies, ensuring efficacy and cost-efficiency in cell-based strategies.